SCHEMBL3675895

SCHEMBL3675895

CCCCOC(=O)c1ccc2c(c1)C(=O)N(OC(C)=O)C2=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
LMNA P02545 3/20 0.56
ESR1 P03372 8/20 0.49
CYP1A2 P05177 2/20 0.49
TSHR P16473 2/20 0.49
CYP2C19 P33261 2/20 0.49
MAPK1 P28482 2/20 0.49
CYP2D6 P10635 1/20 0.49
NR1H2 P55055 1/20 0.49
RNASEL Q05823 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
PDE4D Q08499 1/20 0.48
HPGD P15428 1/20 0.47
RECQL P46063 1/20 0.47
MET P08581 1/20 0.43
STS P08842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3674677 0.96 ALDH1A1 (0.62) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3684004 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3682134 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3677189 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3682431 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3684168 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3676878 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3675758 0.95 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3676316 0.92 LMNA (0.65) ALDH1A1MEN1KMT2ALMNAESR1
SCHEMBL3681449 0.87 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ALMNAESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741514-B2 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst ISHII YASUTAKA 2006-12-14 US disclosed
US-7115541-B2 Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-10-03 US disclosed
EP-1338336-A1 CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS Daicel Chemical Industries, Ltd. (JP) 2003-08-27 EP disclosed
US-20030013603-A1 Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst NOS2, NOS1, NOS3 ALDH1A1 1638/4885MEN1 2032/4885KMT2A 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.